Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label 177Lu-PSMA-I&T trial in Japanese patients with PSMA-positive metastatic castration-resistant prostate cancer
jRCT2011250026Phase 2Recruiting
- Sponsor
- PDRadiopharma Inc.
- Start
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T in prostate cancer (PCa), sponsored by PDRadiopharma Inc. Primary endpoint: Best overall response rate. Started Jan 2026; status: recruiting.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2011250026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250026.